Acumen Pharmaceuticals, Inc.
ABOS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001576885
No open-market purchases or sales by Acumen Pharmaceuticals, Inc. insiders were filed in the last 90 days; 96 institutions reported holding it in 13F filings for Q2 2026, worth $127.8M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +13 vs. previous quarter
- 96
- 13F valueReported value at the end of Q2 2026
- $127.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding ABOS, Q2 2026
No superinvestor reported holding ABOS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Acumen Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 17, 2026 (view filing) | Jun 15-17 | 2 days | Porter DerrellDirector | SSale | −32.3K | $2.33 | −$75.4K | −47.6%35.5K after | 3 lots |
| Jun 10, 2026 (view filing) | Jun 9 | 1 day | Fountain Nathan BDirector | SSale | −6.40K | $2.23 | −$14.3K | −11.7%48.1K after | |
| Mar 10, 2026 (view filing) | Mar 6 | 4 days | Meisner Derek MChief Legal Officer & Corp Sec | SSale | −2.09K | $3.26 | −$6.81K | −1.2%174.0K after | 10b5-1 |
| Mar 3, 2026 (view filing) | Feb 27 | 4 days | Meisner Derek MChief Legal Officer & Corp Sec | SSale | −9.41K | $3.01 | −$28.3K | −5.1%174.0K after | 10b5-1 |
| Jan 28, 2026 (view filing) | Jan 26-28 | 2 days | Meisner Derek MChief Legal Officer & Corp Sec | SSale | −17.8K | $3.00 | −$53.3K | −9.3%174.0K after | 2 lots10b5-1 |
| Jan 23, 2026 (view filing) | Jan 21-23 | 2 days | Meisner Derek MChief Legal Officer & Corp Sec | SSale | −8.93K | $1.87 | −$16.7K | −4.9%174.0K after | 3 lots |
| Jan 23, 2026 (view filing) | Jan 21-22 | 2 days | Siemers EricChief Medical Officer | SSale | −3.23K | $1.81 | −$5.82K | −1.2%255.4K after | 2 lots |
| Jan 23, 2026 (view filing) | Jan 21-22 | 2 days | Zuga MattCFO & Chief Business Officer | SSale | −4.16K | $1.83 | −$7.61K | −1.3%304.9K after | 2 lots |
| Jan 23, 2026 (view filing) | Jan 21-22 | 2 days | OConnell Daniel JosephChief Executive Officer | SSale | −12.0K | $1.83 | −$22.0K | −1.3%881.3K after | 2 lots |
| Jan 23, 2026 (view filing) | Jan 21-22 | 2 days | Barton RussellChief Operating Officer | SSale | −2.78K | $1.81 | −$5.04K | −1.3%205.1K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Acumen Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 20,992,669 | $56.1M | 0.49% | 00.0% | Unchanged |
| Sands Capital Ventures, LLC | 3,720,105 | $9.93M | 1.62% | 00.0% | Unchanged |
| BlackRock, Inc. | 2,490,115 | $6.65M | 0.00% | +2,311,789+1,296.4% | Added |
| Alyeska Investment Group, L.P. | 2,454,754 | $6.55M | 0.02% | 00.0% | Unchanged |
| Franklin Resources Inc | 2,305,096 | $6.15M | 0.00% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 2,111,334 | $5.64M | 0.26% | −45,000−2.1% | Reduced |
| Vanguard Capital Management LLC | 1,672,072 | $4.46M | 0.00% | +165,795+11.0% | Added |
| Knollwood Investment Advisory, LLC | 1,628,510 | $4.35M | 0.39% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 1,141,858 | $3.05M | 0.00% | +725,620+174.3% | Added |
| Ikarian Capital, LLC | 1,053,797 | $2.81M | 0.46% | 00.0% | Unchanged |